Skip to main content
Top
Published in: Current Treatment Options in Neurology 5/2013

01-10-2013 | PEDIATRIC NEUROLOGY (HS SINGER, SECTION EDITOR)

Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex

Author: Darcy A. Krueger, MD, PhD

Published in: Current Treatment Options in Neurology | Issue 5/2013

Login to get access

Opinion statement

Historically, before the advent of modern imaging and genetic testing, Tuberous Sclerosis Complex (TSC) was more of a diagnostic challenge and less of a treatment challenge. This is because the natural history of TSC was poorly understood and TSC-specific treatments were non-existent. In the current era, diagnosis is more straightforward but management is much more complex. Disease manifestations vary by age, severity, and organ system. Management issues in the first few months of life, including neurologic manifestations, are very different than late childhood, adolescence, and adulthood. With increasing numbers of TSC diagnoses being made prenatally or shortly after birth, the opportunity for interventions that may improve long-term developmental and epilepsy outcomes now may precede the onset of neurological clinical symptoms. Familiarity and anticipation of these neurologic complications and rapid response to their emergence is crucial. Periodic imaging surveillance for development of subependymal giant cell astrocytoma (SEGA), preferably by magnetic resonance imaging (MRI) every 1–3 years, is now standard of care. Early SEGA detection provides opportunity to initiate pharmacologic treatment with everolimus if appropriate, thereby negating the need for invasive surgery. Routine electroencephalography (EEG) in asymptomatic infants for the first year or two of life is becoming increasingly accepted, with treatment initiation of vigabatrin dependent on concerning EEG findings instead of waiting until onset of clinical seizures, the traditional approach. Effective SEGA treatment and optimal seizure control remain principal during the first few decades of life for the clinical neurologist involved in the management of TSC. However, during the same period and extending through adulthood, assessment of TSC-associated neuropsychiatric disorder (TAND) is also key to the best clinical outcome and quality of life for affected individuals and their surrounding family and caregivers.
Literature
1.
go back to reference Bourneville D-M. Encéphalite ou sclérose tubéreuse des circonvolutions cérébrales. Encéphalite ou sclérose tubéreuse des circonvolutions cérébrales [Encephalitis or tuberous sclerosis of the cerebral convolutions]. Archives de Neurologie, Paris. 1881;1:390–412. Bourneville D-M. Encéphalite ou sclérose tubéreuse des circonvolutions cérébrales. Encéphalite ou sclérose tubéreuse des circonvolutions cérébrales [Encephalitis or tuberous sclerosis of the cerebral convolutions]. Archives de Neurologie, Paris. 1881;1:390–412.
2.
go back to reference Von Recklinghausen F. Ein Herz von einem Nuegeborene welches mehrere theils nachaussen, theils nachden Höhlein prominirende Tumoren (Myomen) trug. Ein Herz von einem Nuegeborene welches mehrere theils nachaussen, theils nachden Höhlein prominirende Tumoren (Myomen) trug [A heart of a newborn with partial external and internal prominent tumors (fibroids)]. Monatschr Gebursheklkd. 1862;20:1–2. Von Recklinghausen F. Ein Herz von einem Nuegeborene welches mehrere theils nachaussen, theils nachden Höhlein prominirende Tumoren (Myomen) trug. Ein Herz von einem Nuegeborene welches mehrere theils nachaussen, theils nachden Höhlein prominirende Tumoren (Myomen) trug [A heart of a newborn with partial external and internal prominent tumors (fibroids)]. Monatschr Gebursheklkd. 1862;20:1–2.
3.
go back to reference O'Callaghan F, Shiell A, Osborne J, Martyn C. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;352:318–9.CrossRef O'Callaghan F, Shiell A, Osborne J, Martyn C. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;352:318–9.CrossRef
4.
go back to reference European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–15.CrossRef European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305–15.CrossRef
5.
go back to reference van Slegtenhorst M, deHoogt R, Hermans C, Henske E, Short M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–8.PubMedCrossRef van Slegtenhorst M, deHoogt R, Hermans C, Henske E, Short M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277:805–8.PubMedCrossRef
6.
go back to reference Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005;15:702–13.PubMedCrossRef Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Curr Biol. 2005;15:702–13.PubMedCrossRef
7.••
go back to reference Franz D, Belousova E, Sparagana S, Bebin E, Frost M, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associate702-71d with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2012;381:125–32. This article provides definitive evidence of the benefit of everolimus for the treatment of SEGA in a randomized, double-blinded placebo-controlled design. All of the patients in the treatment group demonstrated some degree of benefit, whereas tumor progression was only observed in the placebo group. Class I evidence.PubMedCrossRef Franz D, Belousova E, Sparagana S, Bebin E, Frost M, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associate702-71d with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2012;381:125–32. This article provides definitive evidence of the benefit of everolimus for the treatment of SEGA in a randomized, double-blinded placebo-controlled design. All of the patients in the treatment group demonstrated some degree of benefit, whereas tumor progression was only observed in the placebo group. Class I evidence.PubMedCrossRef
8.
go back to reference Franz DN, Leonard J, Tudor C, Chuck G, Care M, et al. Rapamycin Causes Regression of Astrocytomas in Tuberous Sclerosis Complex. Ann Neurol. 2006;59:490–8.PubMedCrossRef Franz DN, Leonard J, Tudor C, Chuck G, Care M, et al. Rapamycin Causes Regression of Astrocytomas in Tuberous Sclerosis Complex. Ann Neurol. 2006;59:490–8.PubMedCrossRef
9.•
go back to reference Krueger D, Care M, Agricola K, Tudor C, Mays M, et al. Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma. Neurology. 2012;80:574–80. This article provides most up to date evidence of long-term safety and efficacy of everolimus for medical management of SEGA. Treatment continues to be well-tolerated and prevents tumor progression median treatment duration of 34.2 months. Class III evidence.CrossRef Krueger D, Care M, Agricola K, Tudor C, Mays M, et al. Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma. Neurology. 2012;80:574–80. This article provides most up to date evidence of long-term safety and efficacy of everolimus for medical management of SEGA. Treatment continues to be well-tolerated and prevents tumor progression median treatment duration of 34.2 months. Class III evidence.CrossRef
10.
go back to reference Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801–11.PubMedCrossRef Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363:1801–11.PubMedCrossRef
11.
go back to reference Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;[Epub ahead of print]. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;[Epub ahead of print].
12.
go back to reference Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51.PubMedCrossRef Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51.PubMedCrossRef
13.
go back to reference Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario Jr FJ, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: Kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE. 2011;6. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario Jr FJ, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: Kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE. 2011;6.
14.
go back to reference Davies DM, De Vries PJ, Johnson SR, McCartney DL, Cox JA, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071–81.PubMedCrossRef Davies DM, De Vries PJ, Johnson SR, McCartney DL, Cox JA, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071–81.PubMedCrossRef
15.
go back to reference McCormack F, Inoue Y, Moss J, Singer L, Strange C, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–606.PubMedCrossRef McCormack F, Inoue Y, Moss J, Singer L, Strange C, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–606.PubMedCrossRef
16.
go back to reference Foster R, Bint L, Halbert A. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53:52–6.PubMedCrossRef Foster R, Bint L, Halbert A. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53:52–6.PubMedCrossRef
17.
go back to reference Haemel A, O'Brian A, Teng J. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715–8.PubMedCrossRef Haemel A, O'Brian A, Teng J. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146:715–8.PubMedCrossRef
18.
go back to reference Koenig M, Hebert A, Roberson J, Samueals J, Slopis J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topical applied rapamycin. Drugs R&D. 2012;12:121–6.CrossRef Koenig M, Hebert A, Roberson J, Samueals J, Slopis J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topical applied rapamycin. Drugs R&D. 2012;12:121–6.CrossRef
19.
go back to reference Mutizwa M, Berk D, Anadkat M. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(−1) ) in two patients with tuberous sclerosis. Br J Dermatol. 2011;165:922–3.PubMedCrossRef Mutizwa M, Berk D, Anadkat M. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(−1) ) in two patients with tuberous sclerosis. Br J Dermatol. 2011;165:922–3.PubMedCrossRef
20.
go back to reference Demir H, Ekici F, Yazal Erdem A, Emir S, Tunç B. Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics. 2012;130:e243–7.PubMedCrossRef Demir H, Ekici F, Yazal Erdem A, Emir S, Tunç B. Everolimus: a challenging drug in the treatment of multifocal inoperable cardiac rhabdomyoma. Pediatrics. 2012;130:e243–7.PubMedCrossRef
21.
go back to reference Tiberio D, Franz D, Phillips J. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Pediatrics. 2011;127:e1335–7.PubMedCrossRef Tiberio D, Franz D, Phillips J. Regression of a cardiac rhabdomyoma in a patient receiving everolimus. Pediatrics. 2011;127:e1335–7.PubMedCrossRef
22.
go back to reference Krueger D, Wilfong A, Holland-Bouley K, Anderson A, Agricola K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013. doi:10.1002/ana.23960. Krueger D, Wilfong A, Holland-Bouley K, Anderson A, Agricola K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013. doi:10.​1002/​ana.​23960.
23.
go back to reference Adams R, Victor M. Principles of neurology. New York: McGraw-Hill; 1985. p. 1186. Adams R, Victor M. Principles of neurology. New York: McGraw-Hill; 1985. p. 1186.
24.
go back to reference Menkes J, Maria B. Neurocutaneous syndromes. In: Menkes J, Sarnat H, editors. Child Neurology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 865–72. Menkes J, Maria B. Neurocutaneous syndromes. In: Menkes J, Sarnat H, editors. Child Neurology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 865–72.
25.
go back to reference Zhou J, Shrikhande G, Xu J, McKay R, Burns D, et al. Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle. Genes Dev. 2011;25:1595–600.PubMedCrossRef Zhou J, Shrikhande G, Xu J, McKay R, Burns D, et al. Tsc1 mutant neural stem/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle. Genes Dev. 2011;25:1595–600.PubMedCrossRef
26.
go back to reference Way S, McKenna III J, Mietzsch U, Reith R, Wu H, et al. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Gen. 2009;18:1252–65.PubMedCrossRef Way S, McKenna III J, Mietzsch U, Reith R, Wu H, et al. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Gen. 2009;18:1252–65.PubMedCrossRef
27.
go back to reference Carlson B, Houser O, Gomez M. Brain imaging in the tuberous sclerosis complex. In: Gomez M, Sampson J, Whittemore V, editors. Tuberous sclerosis complex. 3rd ed. New York: Oxford University Press; 1999. p. 85–100. Carlson B, Houser O, Gomez M. Brain imaging in the tuberous sclerosis complex. In: Gomez M, Sampson J, Whittemore V, editors. Tuberous sclerosis complex. 3rd ed. New York: Oxford University Press; 1999. p. 85–100.
28.
go back to reference Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13:624–8.PubMedCrossRef Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol. 1998;13:624–8.PubMedCrossRef
29.
go back to reference Inoue Y, Nemoto Y, Murata R, Tashiro T, Shakudo M, et al. CT and MR imaging of cerebral tuberous sclerosis. Brain Dev. 1998;20:209–21.PubMedCrossRef Inoue Y, Nemoto Y, Murata R, Tashiro T, Shakudo M, et al. CT and MR imaging of cerebral tuberous sclerosis. Brain Dev. 1998;20:209–21.PubMedCrossRef
30.
go back to reference Kalantari BN, Salamon N. Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging. Am J Roentgenol. 2008;190:W304–9.CrossRef Kalantari BN, Salamon N. Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging. Am J Roentgenol. 2008;190:W304–9.CrossRef
31.
go back to reference Crino P, Mehta R, Vinters H. Pathogenesis of TSC in the brain. In: Kwiatkowsi D, Whittemore V, Thiele E, editors. Tuberous sclerosis complex: genes, clinical features, and therapeutics. Weinheim: Wiley-Blackwell; 2010. p. 285–309. Crino P, Mehta R, Vinters H. Pathogenesis of TSC in the brain. In: Kwiatkowsi D, Whittemore V, Thiele E, editors. Tuberous sclerosis complex: genes, clinical features, and therapeutics. Weinheim: Wiley-Blackwell; 2010. p. 285–309.
32.
go back to reference Kim SK, Wang KC, Cho BK, Jung HW, Lee YJ, et al. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neuro-Oncol. 2001;52:217–25.CrossRef Kim SK, Wang KC, Cho BK, Jung HW, Lee YJ, et al. Biological behavior and tumorigenesis of subependymal giant cell astrocytomas. J Neuro-Oncol. 2001;52:217–25.CrossRef
33.
go back to reference Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, et al. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol. 2009;16:691–6.PubMedCrossRef Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, et al. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol. 2009;16:691–6.PubMedCrossRef
34.
go back to reference Phi JH, Park SH, Chae JH, Hong KH, Park SS, et al. Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells. Child Nerv Syst. 2008;24:1499–503.CrossRef Phi JH, Park SH, Chae JH, Hong KH, Park SS, et al. Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells. Child Nerv Syst. 2008;24:1499–503.CrossRef
35.
go back to reference Raju GP, Urion DK, Sahin M. Neonatal Subependymal Giant Cell Astrocytoma: new case and review of literature. Pediatr Neurol. 2007;36:128–31.PubMedCrossRef Raju GP, Urion DK, Sahin M. Neonatal Subependymal Giant Cell Astrocytoma: new case and review of literature. Pediatr Neurol. 2007;36:128–31.PubMedCrossRef
36.
go back to reference Shepherd CW, Scheithauer B, Gomez MR. Brain tumors in tuberous sclerosis. A clinicopathologic study of the Mayo Clinic experience. Ann N Y Acad Sci. 1991;615:378–9.PubMedCrossRef Shepherd CW, Scheithauer B, Gomez MR. Brain tumors in tuberous sclerosis. A clinicopathologic study of the Mayo Clinic experience. Ann N Y Acad Sci. 1991;615:378–9.PubMedCrossRef
37.
go back to reference Buccoliero A, Franchi A, Castiglione F, Gheri C, Mussa F, et al. Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology. 2009;29:25–30.PubMedCrossRef Buccoliero A, Franchi A, Castiglione F, Gheri C, Mussa F, et al. Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology. 2009;29:25–30.PubMedCrossRef
38.
go back to reference Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Child Nerv Syst. 2003;19:232–43. Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Child Nerv Syst. 2003;19:232–43.
39.
go back to reference The International Tuberous Sclerosis Complex Consensus Group. “Recommendations for surveillance and management in tuberous sclerosis complex: 2012 update of the International Tuberous Sclerosis Complex Consensus Conference.” Presented at the 2013 International Research Conference on Tuberous Sclerosis Complex and Related Disorders, Washington, DC, June 20–23, 2014. The International Tuberous Sclerosis Complex Consensus Group. “Recommendations for surveillance and management in tuberous sclerosis complex: 2012 update of the International Tuberous Sclerosis Complex Consensus Conference.” Presented at the 2013 International Research Conference on Tuberous Sclerosis Complex and Related Disorders, Washington, DC, June 20–23, 2014.
40.
go back to reference Thiele EA. Managing epilepsy in tuberous sclerosis complex. J Child Neurol. 2004;19:680–6.PubMed Thiele EA. Managing epilepsy in tuberous sclerosis complex. J Child Neurol. 2004;19:680–6.PubMed
41.•
go back to reference Jóźwiak S, Kotulska K, Domańska-Pakieła D, Łojszczyk B, Syczewska M, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediat Neurol. 2011;15:424–31. This paradigm shifting article introduces a prospective, preventative approach towards seizure control rather than the traditional reactionary approach of waiting until after the onset of clinical seizures in infants with TSC. As a result, those infants treated prospectively demonstrated improved long-term seizure control and developmental progress. Class III evidence.CrossRef Jóźwiak S, Kotulska K, Domańska-Pakieła D, Łojszczyk B, Syczewska M, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediat Neurol. 2011;15:424–31. This paradigm shifting article introduces a prospective, preventative approach towards seizure control rather than the traditional reactionary approach of waiting until after the onset of clinical seizures in infants with TSC. As a result, those infants treated prospectively demonstrated improved long-term seizure control and developmental progress. Class III evidence.CrossRef
42.
go back to reference Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediat Neurol. 2002;6:15–23.CrossRef Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediat Neurol. 2002;6:15–23.CrossRef
43.
go back to reference de Vries P. Neurodevelopmental, Psychiatric and Cognitive Aspects of Tuberous Sclerosis Complex. In: Kwiatkowsi DJ, Whittemore VH, Thiele EA, editors. Tuberous Sclerosis Complex. Weinheim: Wiley-Blackwell; 2010. p. 229–68.CrossRef de Vries P. Neurodevelopmental, Psychiatric and Cognitive Aspects of Tuberous Sclerosis Complex. In: Kwiatkowsi DJ, Whittemore VH, Thiele EA, editors. Tuberous Sclerosis Complex. Weinheim: Wiley-Blackwell; 2010. p. 229–68.CrossRef
44.
go back to reference Leclezio L, de Vries P. The Tuberous Sclerosis Complex Associated Neuropsychiatrif Disorders (TAND) Checklist- Pilot validation of a new screening tool for neurophsyciatric manifestations of TSC. Washington, DC.2013. Leclezio L, de Vries P. The Tuberous Sclerosis Complex Associated Neuropsychiatrif Disorders (TAND) Checklist- Pilot validation of a new screening tool for neurophsyciatric manifestations of TSC. Washington, DC.2013.
45.
go back to reference De Vries P, Humphrey A, McCartney D, Prather P, Bolton P, et al. Consensus clinical guidelines for the assessment of cognitive and behavioral problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatr. 2005;14:183–90.CrossRef De Vries P, Humphrey A, McCartney D, Prather P, Bolton P, et al. Consensus clinical guidelines for the assessment of cognitive and behavioral problems in Tuberous Sclerosis. Eur Child Adolesc Psychiatr. 2005;14:183–90.CrossRef
46.
go back to reference Stafstrom CE, Bough KJ. The Ketogenic Diet for the Treatment of Epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci. 2003;6:67–79.PubMedCrossRef Stafstrom CE, Bough KJ. The Ketogenic Diet for the Treatment of Epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci. 2003;6:67–79.PubMedCrossRef
47.
go back to reference Kossoff E, Thiele E, Pfeifer H, McGrogan J, Freeman J. Tuberous sclerosis complex and the ketogenic diet. Epilepsia. 2005;46:1684–6.PubMedCrossRef Kossoff E, Thiele E, Pfeifer H, McGrogan J, Freeman J. Tuberous sclerosis complex and the ketogenic diet. Epilepsia. 2005;46:1684–6.PubMedCrossRef
48.
go back to reference Coppola G, Klepper J, Ammendola E, Fiorillo M, Corte R, et al. The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis. Eur J Paediat Neurol. 2006;10:148–51.CrossRef Coppola G, Klepper J, Ammendola E, Fiorillo M, Corte R, et al. The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis. Eur J Paediat Neurol. 2006;10:148–51.CrossRef
49.
go back to reference Larson AM, Pfeifer HH, Thiele EA. Low glycemic index treatment for epilepsy in tuberous sclerosis complex. Epilepsy Res. 2012;99(1–2):180–2 Larson AM, Pfeifer HH, Thiele EA. Low glycemic index treatment for epilepsy in tuberous sclerosis complex. Epilepsy Res. 2012;99(1–2):180–2
50.
go back to reference Agricola K, Tudor C, Krueger D, Franz D. Nursing implications for the lifelong management of tuberous sclerosis complex. J Neurosci Nurs. 2013(in press). Agricola K, Tudor C, Krueger D, Franz D. Nursing implications for the lifelong management of tuberous sclerosis complex. J Neurosci Nurs. 2013(in press).
51.
go back to reference Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28:5422–32.PubMedCrossRef Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28:5422–32.PubMedCrossRef
52.
go back to reference Meikle L, Talos D, Onda H, Pollizzi K, Rotenberg A, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007;27:5546–58.PubMedCrossRef Meikle L, Talos D, Onda H, Pollizzi K, Rotenberg A, et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci. 2007;27:5546–58.PubMedCrossRef
53.
go back to reference Muncy J, Butler IJ, Koenig M. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol. 2009;24:477.PubMedCrossRef Muncy J, Butler IJ, Koenig M. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol. 2009;24:477.PubMedCrossRef
54.
go back to reference Zeng L, Rensing N, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci. 2009;29:6964–72.PubMedCrossRef Zeng L, Rensing N, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci. 2009;29:6964–72.PubMedCrossRef
55.
go back to reference Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63:444–53.PubMedCrossRef Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008;63:444–53.PubMedCrossRef
56.
go back to reference McDaniel S, Rensing N, Thio L, Yamada K, Wong M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011;52:e7–11.PubMedCrossRef McDaniel S, Rensing N, Thio L, Yamada K, Wong M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011;52:e7–11.PubMedCrossRef
57.
go back to reference Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, et al. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med. 2008;14:843–8.PubMedCrossRef Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, et al. Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis. Nat Med. 2008;14:843–8.PubMedCrossRef
58.
go back to reference Ehninger D, Silva AJ. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med. 2011;17:78–87.PubMedCrossRef Ehninger D, Silva AJ. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. Trends Mol Med. 2011;17:78–87.PubMedCrossRef
59.
go back to reference Go C, Mackay M, Weiss S, Stephens D, Addams-Webber T, et al. Evidence-based guideline update: medical treatment of infantile spasms. Neurology. 2012;78:1974–80.PubMedCrossRef Go C, Mackay M, Weiss S, Stephens D, Addams-Webber T, et al. Evidence-based guideline update: medical treatment of infantile spasms. Neurology. 2012;78:1974–80.PubMedCrossRef
60.
go back to reference Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008;49:1186–91.PubMedCrossRef Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia. 2008;49:1186–91.PubMedCrossRef
61.
go back to reference Greiner H, Lynch E, Fordyce S, Agricola K, Tudor C, et al. Vigabatrin for childhood partial-onset epilepsies. Pediat Neurol. 2012;46:83–8.PubMedCrossRef Greiner H, Lynch E, Fordyce S, Agricola K, Tudor C, et al. Vigabatrin for childhood partial-onset epilepsies. Pediat Neurol. 2012;46:83–8.PubMedCrossRef
62.
go back to reference Kinirons P, Cavalleri G, O'Rourke D, Doherty C, Reid I, et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia. 2006;47:311–7.PubMedCrossRef Kinirons P, Cavalleri G, O'Rourke D, Doherty C, Reid I, et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia. 2006;47:311–7.PubMedCrossRef
63.
go back to reference Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol. 2009;65:98–107.PubMedCrossRef Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol. 2009;65:98–107.PubMedCrossRef
64.
go back to reference Collins J, Tudor C, Leonard J, Chuck G, Franz D. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006;21:53–7.PubMedCrossRef Collins J, Tudor C, Leonard J, Chuck G, Franz D. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006;21:53–7.PubMedCrossRef
65.
go back to reference Franz D, Leonard J, Tudor C, Chuck G, Egelhoff J. Levetiracetam therapy of epilepsy in tuberous sclerosis. J Child Neurol. 2001;16:679. Franz D, Leonard J, Tudor C, Chuck G, Egelhoff J. Levetiracetam therapy of epilepsy in tuberous sclerosis. J Child Neurol. 2001;16:679.
66.
go back to reference Franz D, Leonard J, Tudor C, Chuck G, Egelhoff J. Oxcarbazepine therapy of epilepsy in tuberous sclerosis. J Child Neurol. 2001;16:680. Franz D, Leonard J, Tudor C, Chuck G, Egelhoff J. Oxcarbazepine therapy of epilepsy in tuberous sclerosis. J Child Neurol. 2001;16:680.
67.
go back to reference Franz D, Tudor C, Leonard J. Topiramate as therapy for tuberous sclerosis complex-associated seizures. Epilepsia. 2000;41:87. Franz D, Tudor C, Leonard J. Topiramate as therapy for tuberous sclerosis complex-associated seizures. Epilepsia. 2000;41:87.
68.
go back to reference Franz D, Tudor C, Leonard J, Egelhoff J, Byars A, et al. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia. 2001;42:935–40.PubMedCrossRef Franz D, Tudor C, Leonard J, Egelhoff J, Byars A, et al. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia. 2001;42:935–40.PubMedCrossRef
69.
go back to reference Franz DN, Tudor C, Leonard J, Egelhoff JC, Byars A, et al. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia. 2001;42:935–40.PubMedCrossRef Franz DN, Tudor C, Leonard J, Egelhoff JC, Byars A, et al. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia. 2001;42:935–40.PubMedCrossRef
70.
go back to reference Chung T, Lynch E, Fiser C, Nelson D, Agricola K, et al. Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex. Ann Clin Psychiatr. 2011;23:263–9. Chung T, Lynch E, Fiser C, Nelson D, Agricola K, et al. Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex. Ann Clin Psychiatr. 2011;23:263–9.
71.
go back to reference Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Pediatr Drugs. 2008;10:299–313.CrossRef Krueger DA, Franz DN. Current management of tuberous sclerosis complex. Pediatr Drugs. 2008;10:299–313.CrossRef
72.
go back to reference Jozwiak J, Jozwiak S, Oldak M. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev. 2006;26:160–80.PubMedCrossRef Jozwiak J, Jozwiak S, Oldak M. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment. Med Res Rev. 2006;26:160–80.PubMedCrossRef
74.
go back to reference Berhouma M. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr. 2010;6:103–10.PubMedCrossRef Berhouma M. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr. 2010;6:103–10.PubMedCrossRef
75.
go back to reference de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard J, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60:83–9.PubMedCrossRef de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard J, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60:83–9.PubMedCrossRef
76.
go back to reference Moavero R, Pinci M, Bombardieri R, Curatolo P. The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Child Nervous Syst. 2011;27:1203–10.CrossRef Moavero R, Pinci M, Bombardieri R, Curatolo P. The management of subependymal giant cell tumors in tuberous sclerosis: a clinician's perspective. Child Nervous Syst. 2011;27:1203–10.CrossRef
77.
go back to reference Sun P, Kohrman M, Liu J, Guo A, Rogerio J, et al. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin. 2012;28:657–63.PubMedCrossRef Sun P, Kohrman M, Liu J, Guo A, Rogerio J, et al. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin. 2012;28:657–63.PubMedCrossRef
78.
go back to reference Franz D, Agricola KD, Tudor C, Krueger D. Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma assocaited with tuberous sclerosis complex. J Child Neurol. 2012;28:602–7.PubMedCrossRef Franz D, Agricola KD, Tudor C, Krueger D. Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma assocaited with tuberous sclerosis complex. J Child Neurol. 2012;28:602–7.PubMedCrossRef
79.
go back to reference Connolly MB, Hendson G, Steinbok P. Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. Child Nerv Syst. 2006;22:896–908.CrossRef Connolly MB, Hendson G, Steinbok P. Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects. Child Nerv Syst. 2006;22:896–908.CrossRef
80.
go back to reference Koh S, Jayakar P, Dunoyer C, Whiting SE, Resnick TJ, et al. Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome. Epilepsia. 2000;41:1206–13.PubMedCrossRef Koh S, Jayakar P, Dunoyer C, Whiting SE, Resnick TJ, et al. Epilepsy surgery in children with tuberous sclerosis complex: presurgical evaluation and outcome. Epilepsia. 2000;41:1206–13.PubMedCrossRef
81.
go back to reference Weiner HL, Ferraris N, LaJoie J, Miles D, Devinsky O. Epilepsy surgery for children with tuberous sclerosis complex. J Child Neurol. 2004;19:687–9.PubMed Weiner HL, Ferraris N, LaJoie J, Miles D, Devinsky O. Epilepsy surgery for children with tuberous sclerosis complex. J Child Neurol. 2004;19:687–9.PubMed
82.
go back to reference Elliott RE, Carlson C, Kalhorn SP, Moshel YA, Weiner HL, et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav. 2009;16:454–60.PubMedCrossRef Elliott RE, Carlson C, Kalhorn SP, Moshel YA, Weiner HL, et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav. 2009;16:454–60.PubMedCrossRef
Metadata
Title
Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex
Author
Darcy A. Krueger, MD, PhD
Publication date
01-10-2013
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 5/2013
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-013-0249-2

Other articles of this Issue 5/2013

Current Treatment Options in Neurology 5/2013 Go to the issue

CEREBROVASCULAR DISORDERS (HP ADAMS JR, SECTION EDITOR)

Status of Endovascular Interventions to Treat Acute Ischemic Stroke

CEREBROVASCULAR DISORDERS (HP ADAMS JR, SECTION EDITOR)

Role of Telemedicine in Providing Tertiary Neurological Care